Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 5.62 MB
Add to list
  1. Search results
  2. In vitro transcribed RNA-based platfo...

In vitro transcribed RNA-based platform vaccines : past, present, and future

Alexey D. Perenkov, Alena D. Sergeeva, Maria V. Vedunova and Dmitri Krysko (UGent)
(2023) VACCINES. 11(10).
Author
Organization
Abstract
mRNA was discovered in 1961, but it was not used as a vaccine until after three decades. Recently, the development of mRNA vaccine technology gained great impetus from the pursuit of vaccines against COVID-19. To improve the properties of RNA vaccines, and primarily their circulation time, self-amplifying mRNA and trans-amplifying mRNA were developed. A separate branch of mRNA technology is circular RNA vaccines, which were developed with the discovery of the possibility of translation on their protein matrix. Circular RNA has several advantages over mRNA vaccines and is considered a fairly promising platform, as is trans-amplifying mRNA. This review presents an overview of the mRNA platform and a critical discussion of the more modern self-amplifying mRNA, trans-amplifying mRNA, and circular RNA platforms created on its basis. Finally, the main features, advantages, and disadvantages of each of the presented mRNA platforms are discussed. This discussion will facilitate the decision-making process in selecting the most appropriate platform for creating RNA vaccines against cancer or viral diseases.
Keywords
mRNA vaccine, self-amplifying mRNA vaccine, trans-amplifying mRNA vaccine, circular RNA vaccine, immunogenicity, vaccine, REVERSE CAP ANALOGS, MESSENGER-RNA, CIRCULAR RNAS, CHEMICAL-MODIFICATION, IMMUNE-RESPONSE, GENE-EXPRESSION, 3' UTRS, SELF, TRANSLATION, RECOGNITION

Downloads

  • Download
    Perenkov et al Vaccines 2023.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 5.62 MB

Citation

Please use this url to cite or link to this publication:

MLA
Perenkov, Alexey D., et al. “In Vitro Transcribed RNA-Based Platform Vaccines : Past, Present, and Future.” VACCINES, vol. 11, no. 10, MDPI, 2023, doi:10.3390/vaccines11101600.
APA
Perenkov, A. D., Sergeeva, A. D., Vedunova, M. V., & Krysko, D. (2023). In vitro transcribed RNA-based platform vaccines : past, present, and future. VACCINES, 11(10). https://doi.org/10.3390/vaccines11101600
Chicago author-date
Perenkov, Alexey D., Alena D. Sergeeva, Maria V. Vedunova, and Dmitri Krysko. 2023. “In Vitro Transcribed RNA-Based Platform Vaccines : Past, Present, and Future.” VACCINES 11 (10). https://doi.org/10.3390/vaccines11101600.
Chicago author-date (all authors)
Perenkov, Alexey D., Alena D. Sergeeva, Maria V. Vedunova, and Dmitri Krysko. 2023. “In Vitro Transcribed RNA-Based Platform Vaccines : Past, Present, and Future.” VACCINES 11 (10). doi:10.3390/vaccines11101600.
Vancouver
1.
Perenkov AD, Sergeeva AD, Vedunova MV, Krysko D. In vitro transcribed RNA-based platform vaccines : past, present, and future. VACCINES. 2023;11(10).
IEEE
[1]
A. D. Perenkov, A. D. Sergeeva, M. V. Vedunova, and D. Krysko, “In vitro transcribed RNA-based platform vaccines : past, present, and future,” VACCINES, vol. 11, no. 10, 2023.
@article{01HG8J07J5RWK70E4MK7Q5TMBW,
  abstract     = {{mRNA was discovered in 1961, but it was not used as a vaccine until after three decades. Recently, the development of mRNA vaccine technology gained great impetus from the pursuit of vaccines against COVID-19. To improve the properties of RNA vaccines, and primarily their circulation time, self-amplifying mRNA and trans-amplifying mRNA were developed. A separate branch of mRNA technology is circular RNA vaccines, which were developed with the discovery of the possibility of translation on their protein matrix. Circular RNA has several advantages over mRNA vaccines and is considered a fairly promising platform, as is trans-amplifying mRNA. This review presents an overview of the mRNA platform and a critical discussion of the more modern self-amplifying mRNA, trans-amplifying mRNA, and circular RNA platforms created on its basis. Finally, the main features, advantages, and disadvantages of each of the presented mRNA platforms are discussed. This discussion will facilitate the decision-making process in selecting the most appropriate platform for creating RNA vaccines against cancer or viral diseases.}},
  articleno    = {{1600}},
  author       = {{Perenkov, Alexey D. and  Sergeeva, Alena D. and  Vedunova, Maria V. and Krysko, Dmitri}},
  issn         = {{2076-393X}},
  journal      = {{VACCINES}},
  keywords     = {{mRNA vaccine,self-amplifying mRNA vaccine,trans-amplifying mRNA vaccine,circular RNA vaccine,immunogenicity,vaccine,REVERSE CAP ANALOGS,MESSENGER-RNA,CIRCULAR RNAS,CHEMICAL-MODIFICATION,IMMUNE-RESPONSE,GENE-EXPRESSION,3' UTRS,SELF,TRANSLATION,RECOGNITION}},
  language     = {{eng}},
  number       = {{10}},
  pages        = {{31}},
  publisher    = {{MDPI}},
  title        = {{In vitro transcribed RNA-based platform vaccines : past, present, and future}},
  url          = {{http://doi.org/10.3390/vaccines11101600}},
  volume       = {{11}},
  year         = {{2023}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: